SCHEMBL4614527

SCHEMBL4614527

CCCCn1c(=O)[nH]c(=O)c2[nH]c(C(Cc3ccccc3F)c3ccc(NS(=O)(=O)c4ccc(OC(F)(F)F)cc4)cc3)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCK1 P35558 7/20 0.41
ADORA2B P29275 3/20 0.37
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
SERPINE1 P05121 1/20 0.36
MAPT P10636 1/20 0.36
ADORA2A P29274 2/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
KCNH2 Q12809 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4615436 0.93 KDM4E (0.41) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4614552 0.92 PCK1 (0.44) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4615996 0.91 KDM4E (0.41) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4614679 0.91 PCK1 (0.44) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4614662 0.91 PCK1 (0.42) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4615595 0.90 PCK1 (0.42) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4613809 0.90 PCK1 (0.41) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4614787 0.90 PCK1 (0.41) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4614819 0.90 PCK1 (0.43) PCK1ADORA2BKDM4EMEN1ALDH1A1
SCHEMBL4612939 0.89 PCK1 (0.40) PCK1ADORA2BKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US claimed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US claimed
EP-1599477-B1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-30 EP disclosed
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US disclosed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192708-A1 Sulfonamide substituted xanthine derivatives GYS2, SLC5A1, SLC5A2 PCK1 36/4885ADORA2B 1069/4885KDM4E 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.